Adverum Biotechnologies Inc. held its Annual Meeting of Stockholders on June 17, 2025. During the meeting, stockholders elected Laurent Fischer, M.D., Patrick Machado, and James Scopa as Class II directors. Additionally, stockholders approved the amendment and restatement of the 2024 Equity Incentive Award Plan and the amendment of certain outstanding stock options to reduce the exercise price per share.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.